Apogee Therapeutics Inc (APGE) 뉴스

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq:...

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week...

Form 4 - Statement of changes in beneficial ownership of securities

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

Form 4 - Statement of changes in beneficial ownership of securities